Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Svensson, B.
Right arrow Articles by Theander, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svensson, B.
Right arrow Articles by Theander, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 1031-1036
© 2000 British Society for Rheumatology

Remission and response to early treatment of RA assessed by the Disease Activity Score

B. Svensson, C. Schaufelberger1, A. Teleman and J. Theander2 for the BARFOT study group

Spenshult's Hospital for Rheumatic Diseases and Rehabilitation, Halmstad,
1 Department of Rheumatology, Sahlgrenska University Hospital, Mölndal and
2 Rheumatology Section, Kristianstad County Hospital, Kristianstad, Sweden

Objective. To assess criteria for individual response and remission based on the Disease Activity Score (DAS) in patients with RA participating in a long-term observational study.

Methods. The EULAR (European League against Rheumatism) criteria for individual response and a recently proposed remission criterion, DAS <1.6, were applied to 90 patients with RA after treatment for 2 yr with disease-modifying anti-rheumatic drugs (DMARDs) and/or corticosteroids.

Results. Seventy-six per cent of the patients were classified as responders (46% good and 30% moderate responders). Good responders had significantly more improvement in pain and Health Assessment Questionnaire (HAQ) score than moderate responders and non-responders. Paired comparisons showed significant X-ray progression both for moderate responders and non-responders but not for good responders. Twenty-nine per cent of all responders had an end-point DAS >2.4, indicating active disease. In this group of responders, X-ray changes progressed significantly, but this could not be demonstrated in the group of responders with DAS <=2.4. Thirty-six per cent of the 90 patients included in the study were classified as being in remission after 2 yr of treatment. The group of patients in remission showed no evidence of X-ray progression after 2 yr.

Conclusions. Response and remission criteria based on DAS were useful in a study of patients with RA who were managed essentially as in clinical practice. The criteria used showed construct and criterion validity, although discriminant validity could not be shown. The application of valid criteria for response and remission in clinical practice may be a useful aid in the evaluation of treatment effects and in making treatment decisions for individual patients.

KEY WORDS: Early rheumatoid arthritis, Individual response criteria, Remission criteria, Disease Activity Score.

Correspondence to: B. Svensson, Blistorpsvägen 105, S-290 38 V. Vånga, Sweden.

M. Ahlmén, I. Hafström, C. Keller, I. Leden, B. Lindell, I. Petersson, D. Sahlberg, C. Schaufelberger, L. Sköldstam, B. Svensson, A. Teleman and J. Theander.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
B.-M. Nyhall-Wahlin, I. F. Petersson, J.-A. Nilsson, L. T. H. Jacobsson, C. Turesson, and the BARFOT study group
High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis
Rheumatology, April 1, 2009; 48(4): 416 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Karonitsch, D Aletaha, M Boers, S Bombardieri, B Combe, M Dougados, P Emery, D Felson, J Gomez-Reino, E Keystone, et al.
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
Ann Rheum Dis, October 1, 2008; 67(10): 1365 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
G Cohen, L Gossec, M Dougados, A Cantagrel, P Goupille, J. Daures, N Rincheval, and B Combe
Radiological damage in patients with rheumatoid arthritis on sustained remission
Ann Rheum Dis, March 1, 2007; 66(3): 358 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
K Forslind, I Hafstrom, M Ahlmen, B Svensson, and for the BARFOT Study Group
Sex: a major predictor of remission in early rheumatoid arthritis?
Ann Rheum Dis, January 1, 2007; 66(1): 46 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Orozco, G. Robledo, M. V. P. Linga Reddy, A. Garcia, D. Pascual-Salcedo, A. Balsa, M. A. Gonzalez-Gay, A. Eimon, S. Paira, H. R. Scherbarth, et al.
Study of the role of a functional polymorphism of MHC2TA in rheumatoid arthritis in three ethnically different populations
Rheumatology, November 1, 2006; 45(11): 1442 - 1444.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
K Forslind, M Ahlmen, K Eberhardt, I Hafstrom, and B Svensson
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)
Ann Rheum Dis, September 1, 2004; 63(9): 1090 - 1095.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.